163 related articles for article (PubMed ID: 21325428)
1. Variable expression and treatment of PAPA syndrome.
Schellevis MA; Stoffels M; Hoppenreijs EP; Bodar E; Simon A; van der Meer JW
Ann Rheum Dis; 2011 Jun; 70(6):1168-70. PubMed ID: 21325428
[No Abstract] [Full Text] [Related]
2. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra.
Brenner M; Ruzicka T; Plewig G; Thomas P; Herzer P
Br J Dermatol; 2009 Nov; 161(5):1199-201. PubMed ID: 19673875
[TBL] [Abstract][Full Text] [Related]
3. Anakinra for flares of pyogenic arthritis in PAPA syndrome.
Dierselhuis MP; Frenkel J; Wulffraat NM; Boelens JJ
Rheumatology (Oxford); 2005 Mar; 44(3):406-8. PubMed ID: 15637033
[No Abstract] [Full Text] [Related]
4. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).
Demidowich AP; Freeman AF; Kuhns DB; Aksentijevich I; Gallin JI; Turner ML; Kastner DL; Holland SM
Arthritis Rheum; 2012 Jun; 64(6):2022-7. PubMed ID: 22161697
[TBL] [Abstract][Full Text] [Related]
5. Osteolytic lesion in PAPA syndrome responding to anti-interleukin 1 treatment.
Caorsi R; Picco P; Buoncompagni A; Martini A; Gattorno M
J Rheumatol; 2014 Nov; 41(11):2333-4. PubMed ID: 25362725
[No Abstract] [Full Text] [Related]
6. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab.
Lee H; Park SH; Kim SK; Choe JY; Park JS
Clin Exp Rheumatol; 2012; 30(3):452. PubMed ID: 22513199
[No Abstract] [Full Text] [Related]
7. Clinical efficacy of etanercept for treatment of PAPA syndrome.
Tofteland ND; Shaver TS
J Clin Rheumatol; 2010 Aug; 16(5):244-5. PubMed ID: 20661073
[No Abstract] [Full Text] [Related]
8. Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome.
Omenetti A; Carta S; Caorsi R; Finetti M; Marotto D; Lattanzi B; Jorini M; Delfino L; Penco F; Picco P; Buoncompagni A; Martini A; Rubartelli A; Gattorno M
Rheumatology (Oxford); 2016 Jul; 55(7):1325-35. PubMed ID: 26989109
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.
Sood AK; McShane DB; Googe PB; Wu EY
J Clin Immunol; 2019 Nov; 39(8):832-835. PubMed ID: 31471736
[No Abstract] [Full Text] [Related]
10. Haematological involvement associated with a mild autoinflammatory phenotype, in two patients carrying the E250K mutation of PSTPIP1.
Belelli E; Passarelli C; Pardeo M; Holzinger D; De Benedetti F; Insalaco A
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):113-115. PubMed ID: 28628471
[TBL] [Abstract][Full Text] [Related]
11. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier.
Jennings L; Molloy O; Quinlan C; Kelly G; O'Kane M
Int J Dermatol; 2017 Jun; 56(6):e128-e129. PubMed ID: 28239847
[No Abstract] [Full Text] [Related]
12. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment.
Geusau A; Mothes-Luksch N; Nahavandi H; Pickl WF; Wise CA; Pourpak Z; Ponweiser E; Eckhart L; Sunder-Plassmann R
JAMA Dermatol; 2013 Feb; 149(2):209-15. PubMed ID: 23426477
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne: A Single-Center Experience and Literature Review.
Wang Y; Wu N; Yu K; Shen M
Front Immunol; 2021; 12():735851. PubMed ID: 34745107
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapy of pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome (PAPA): a case report and literature review].
Liang WL; Li HG; Zhong G; Wang BS; Ma JD; Chen JL; Mao HW; Yu-Lung YL; Lee PH
Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):977-981. PubMed ID: 33256319
[No Abstract] [Full Text] [Related]
15. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome.
Braun-Falco M; Kovnerystyy O; Lohse P; Ruzicka T
J Am Acad Dermatol; 2012 Mar; 66(3):409-15. PubMed ID: 21745697
[TBL] [Abstract][Full Text] [Related]
16. Monogenic Auto-inflammatory Syndromes: A Review of the Literature.
Azizi G; Khadem Azarian S; Nazeri S; Mosayebian A; Ghiasy S; Sadri G; Mohebi A; Khan Nazer NH; Afraei S; Mirshafiey A
Iran J Allergy Asthma Immunol; 2016 Dec; 15(6):430-444. PubMed ID: 28129677
[TBL] [Abstract][Full Text] [Related]
17. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
18. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
[No Abstract] [Full Text] [Related]
19. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome.
Stichweh DS; Punaro M; Pascual V
Pediatr Dermatol; 2005; 22(3):262-5. PubMed ID: 15916580
[TBL] [Abstract][Full Text] [Related]
20. Alarming consequences - autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1.
Holzinger D; Roth J
Curr Opin Rheumatol; 2016 Sep; 28(5):550-9. PubMed ID: 27464597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
